SCHEMBL6674052

SCHEMBL6674052

CC(C)(C)OC(=O)NC1CCN(c2c(F)cc3c(=O)[nH]c(=O)n(C4CC4)c3c2Cl)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.40
PIM3 Q86V86 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
OPRM1 P35372 2/20 0.39
OPRD1 P41143 2/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA1C Q13936 1/20 0.38
SCN5A Q14524 1/20 0.38
KDM4D Q6B0I6 2/20 0.38
F10 P00742 1/20 0.38
DDR1 Q08345 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674047 1.00 PIM1 (0.40) PIM1PIM3PIM2OPRM1OPRD1
SCHEMBL7093644 0.85 PIM1 (0.40) PIM1PIM3PIM2KDM4DF10
SCHEMBL7093642 0.85 PIM1 (0.40) PIM1PIM3PIM2KDM4DF10
SCHEMBL4513702 0.84 F10 (0.39) PIM1PIM3PIM2OPRM1OPRD1
SCHEMBL6649040 0.82 EEF2K (0.42) PIM1PIM3PIM2OPRM1OPRD1
SCHEMBL7092547 0.82 EEF2K (0.42) PIM1PIM3PIM2OPRM1OPRD1
SCHEMBL9152277 0.79 ALDH1A1 (0.66) OPRM1OPRD1ALDH1A1POLBCHRM2
SCHEMBL9154014 0.79 ALDH1A1 (0.66) OPRM1OPRD1ALDH1A1POLBCHRM2
SCHEMBL9152269 0.79 ALDH1A1 (0.66) OPRM1OPRD1ALDH1A1POLBCHRM2
SCHEMBL4502431 0.78 F10 (0.41) PIM1PIM3PIM2OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401830-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS Warner-Lambert Company LLC (US) 2004-03-31 EP disclosed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 US disclosed
WO-2002102793-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2002-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance ABCC1, RPS6KA1, SIGMAR1 PIM1 1570/4885PIM3 1524/4885PIM2 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.